Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
Endocrine · 2026 Oct 29 · Arslan T et
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 28 20:00 ETSource: Endocrine
From the source
Read at pubmed.ncbi.nlm.nih.govComparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
Endocrine · 2026 Oct 29 · Arslan T et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42955519/
